Ask AI

Managing the Risk and Impact of Tardive Dyskinesia in Mood Disorder Patients

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 12, 2026

Expiration: October 11, 2027

See Activity Collection

Increasingly, antipsychotics are being used in the treatment of mood disorders, putting these patients at risk for tardive dyskinesia, which can affect functioning and quality of life even when abnormal movements appear mild. This expert-led, on-demand webcast examines risk factors, screening, clinical features, and differential diagnosis and provides practical approaches to monitoring and individualized management strategies, including evidence-based use of VMAT2 inhibitors.

TD in Mood Disorders

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people at risk for developing TD (ie, treated with antipsychotics) do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

How confident do you feel about selecting a treatment option for a patient with tardive dyskinesia?

4.

A 56-yr-old woman with major depressive disorder has received a second-generation antipsychotic as adjunctive treatment. During a routine visit, you notice new, mild intermittent movements of her lips and tongue. She is unaware of the movements. Which additional finding would most increase your concern that these movements represent TD?

5.

In patients receiving treatment with an antipsychotic, what is the most effective screening policy to identify TD?

6.

A 62-yr-old man with stable schizoaffective disorder receiving a mood stabilizer and a second-generation antipsychotic complains of long-standing abnormal involuntary movements. He has a total AIMS score of 9. The most appropriate next step would be: